Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
18h
Patients might not know about Roche Tissue Diagnostics, but the Arizona entity has been testing for cancer and helping devise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback